Evidence map›Paper›PMID 31236668›Full record

SynthesisJournal of cancer research and clinical oncology2019

Human papillomavirus and lung cancer: an overview and a meta-analysis.

M M Tsyganov, A M Pevzner, M K Ibragimova, I V Deryusheva, N V Litviakov

Open access · greenAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

M M TsyganovResearcher Laboratory of Oncovirus, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, st. Cooperative 5, Tomsk, 634009, Russia. TsyganovMM@yandex.ru.ORCID http://orcid.org/0000-0001-7419-4512
A M PevznerResearcher Laboratory of Oncovirus, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, st. Cooperative 5, Tomsk, 634009, Russia.
M K IbragimovaResearcher Laboratory of Oncovirus, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, st. Cooperative 5, Tomsk, 634009, Russia.
I V DeryushevaResearcher Laboratory of Oncovirus, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, st. Cooperative 5, Tomsk, 634009, Russia.
N V LitviakovResearcher Laboratory of Oncovirus, Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences, st. Cooperative 5, Tomsk, 634009, Russia.
Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis review is devoted to assessing the prevalence of human papillomavirus (HPV) in lung cancer (LC) in the world. HPV is recognized as the etiological factor of cervical cancer, however, there is widespread evidence that this virus is detected not only in gynecological carcinomas, but also in tumors of other organs, in particular the upper respiratory tract and digestive tract. MATERIALS AND

methodsA search was conducted to a depth of 29 years in the PubMed, Web of Science, Scopus, databases. The review includes 95 articles.

resultsOf all the analyzed studies (9195 patients), 12 works showed a complete absence of HPV in the biological material in patients with LC. The absence of a virus among lung cancer patients has been established for Canada, the Netherlands and Singapore. The highest average percent of occurrence of this virus is shown for such countries as: Brazil, Korea, Greece and Taiwan (more than 40%). But the highest percentage of HPV occurrence by region is observed in Latin America (33.5%), followed by the Asian countries (31%), in European countries the frequency is 18%. Interestingly, the highest occurrence of high oncogenic types (16 and 18) is observed in Asia (40.3%), then in Latin America (33.6%), Europe (25.6%) and North America (15.4%). Low-oncogenic types (6 and 11) are also predominantly observed in Asia (39.9%), while in Europe and North America 30% and 12.8%, respectively. A meta-analysis of the prevalence of HPV was conducted using Comprehensive Meta-Analysis 3.0. Program, which included 26 studies, the results of which revealed: the prevalence of HPV infection in tumor lung tissue was compared with normal lung tissue OR (95% CI) = 5.38 (3.21-9.00) p < 0.0001, significance was also found for Chinese studies OR = 6.3, 95% CI 3.42-11.53, p < 0.0001, I2 = 71.8% and for nine studies in Europe OR = 6.3, 95% CI 1.8-22.18, p = 0.004, I2 = 51.0%. However, given the fact that the frequency of occurrence of HPV in lung tumor tissue varies greatly, a question may arise about the real role of HPV in LC carcinogenesis, which makes further research relevant and promising.

Indexed as

Carcinoma, Squamous CellFemaleGastrointestinal NeoplasmsGeographyHumansLung NeoplasmsPapillomaviridaePapillomavirus InfectionsPrevalenceUterine Cervical NeoplasmsCase–control studyHPVHuman papillomavirusLung cancerMeta-analysisOverview

Identifiers

PMID31236668
PMCPMC11810214
OpenAlexW2950489632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.